Flossbach Von Storch SE Has $231.71 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Flossbach Von Storch SE increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 16.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 551,764 shares of the company's stock after purchasing an additional 78,428 shares during the quarter. IDEXX Laboratories makes up approximately 1.0% of Flossbach Von Storch SE's holdings, making the stock its 28th largest holding. Flossbach Von Storch SE owned 0.68% of IDEXX Laboratories worth $231,713,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MorganRosel Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at about $26,000. Hurley Capital LLC bought a new position in IDEXX Laboratories during the 4th quarter worth $29,000. Colonial Trust Co SC grew its stake in IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after buying an additional 39 shares during the last quarter. Itau Unibanco Holding S.A. grew its stake in shares of IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Retirement Wealth Solutions LLC grew its stake in shares of IDEXX Laboratories by 40.0% in the first quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock worth $44,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Down 1.4%

Shares of NASDAQ IDXX traded down $7.72 during mid-day trading on Friday, hitting $533.37. 348,343 shares of the company traded hands, compared to its average volume of 646,418. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $549.52. The stock has a market capitalization of $42.89 billion, a price-to-earnings ratio of 49.29, a PEG ratio of 3.94 and a beta of 1.54. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. The business has a 50 day moving average of $518.45 and a two-hundred day moving average of $458.14.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.71 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IDXX. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Stifel Nicolaus increased their price target on IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research note on Wednesday, July 2nd. Morgan Stanley increased their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target for the company. Finally, Leerink Partners upped their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $558.11.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director directly owned 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.